Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PSNL
SellHot AirPersonalis, Inc. · Healthcare · United States · $1.8B · Avg Vol: $54M/d
24
StockRankGet insider-trade alerts
Q
25
V
23
M
64
P/E (TTM)
—
ROE
-50.3%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.0M | 73.5M | 84.6M | 69.6M | 2.3% | 69.7M | 82.5M | 110.2M | 25.8% |
| EPS | -1.09 | -1.06 | -1.37 | -0.91 | — | -1.09 | -1.09 | -0.94 | — |
| Shares | 106.8M | 106.8M | 85.2M | 102.5M | -4.0% | 106.8M | — | — | — |
| Debt | 48.6M | 47.7M | 44.2M | 39.9M | -6.4% | 38.0M | — | — | — |
| Equity | 218.1M | 129.4M | 203.0M | 261.2M | 6.2% | — | — | — | — |
| Op CF | -70.2M | -56.3M | -45.1M | -74.9M | — | -92.3M | — | — | — |
| Inv CF | 52.5M | 13.1M | -35.1M | -22.6M | — | — | — | — | — |
| Fin CF | 1.4M | 11.0M | 114.7M | 130.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+28.0%
SMA 50SMA 200
Close
$16.21
RSI (14)
26.4
52W High
$18.89
From 52W High
0.9%
SCORE BREAKDOWN
Quality
25
ROIC
-36.3%21.1
ROE
-50.3%18.1
GP/Assets
2.6%15.2
Op. Margin
-150.2%15.1
FCF/Assets
-30.2%13.6
Piotroski
430.8
Int. Cover
-50.0x5.8
D/E Ratio
0.16x54.1
Current Ratio
5.28x73.8
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-15.9x25.0
P/FCF
—N/A
P/B
7.8x16.3
P/S
26.4x13.3
Div Yield
—N/A
Momentum
64
52W High %
86%78.9
RS 6M
131%98.3
SMA 50/200
1.47x97.3
EPS Rev 4W
-3.8%15.5
EPS Rev 12W
—N/A
EPS Improve
+14%30.0
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.8B
P/E (Forward)
-18.3x
Gross Margin
12.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PSNL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PSNL | Personalis, Inc.(you) | $1.8B | 24 | Sell |
| WGS | GeneDx Holdings Corp. | $2.6B | 26 | Sell |
| FRNM | Freenome, Inc. | $1.6B | 17 | Strong Sell |
| GRAL | GRAIL, Inc. | $3.6B | 28 | Sell |
| OPK | OPKO Health, Inc. | $1.1B | 40 | Hold |
| CSTL | Castle Biosciences, Inc. | $1.0B | 39 | Hold |
| NEO | NeoGenomics, Inc. | $2.3B | 46 | Hold |
| ADPT | Adaptive Biotechnologies Corporation | $4.0B | 38 | Hold |
| RDNT | RadNet, Inc. | $5.9B | 34 | Sell |
| MYGN | Myriad Genetics, Inc. | $302M | 21 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%